Your session is about to expire
← Back to Search
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Recurrent platinum sensitive ovarian cancer, all histologies (serous, endometrioid, mucinous, clear cell). Platinum sensitivity defined as ≥ 6 months since last platinum treatment.
No contraindication to carboplatin and/or liposomal doxorubicin or simvastatin.
Must not have
Uncontrolled intercurrent illness
Prior or current use of any statin medication
Timeline
Screening 3 weeks
Treatment Varies
Follow Up from baseline until 12 months
Awards & highlights
No Placebo-Only Group
Summary
This trial is testing whether simvastatin can help treat ovarian cancer. 20 patients will be given the drug and monitored for effects on their cancer.
Who is the study for?
This trial is for women with recurrent ovarian cancer that responds to platinum-based chemotherapy, provided they haven't used statins or drugs that interact with them, have no liver disease or uncontrolled illnesses, and don't consume excessive alcohol.
What is being tested?
The study tests the use of Simvastatin 40mg in combination with carboplatin and liposomal doxorubicin on 20 patients at Cedars-Sinai Medical Center to see if it slows down cancer progression in those with platinum-sensitive ovarian cancer.
What are the potential side effects?
Simvastatin may cause muscle pain, weakness, liver problems, digestive issues, blood sugar changes. When combined with chemotherapy drugs like carboplatin and liposomal doxorubicin, side effects can include nausea, fatigue, risk of infection.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowSelect...
My ovarian cancer has returned but responds to platinum treatment.
Select...
I am not allergic or unable to take carboplatin, liposomal doxorubicin, or simvastatin.
Exclusion Criteria
You may be eligible for the trial if you check “No” for criteria below:Select...
I do not have any unmanaged ongoing illnesses.
Select...
I have taken statin medication before or am currently taking it.
Select...
I am currently taking medications that interact with statins.
Select...
I have been treated with doxorubicin or liposomal doxorubicin before.
Select...
I have a long-term muscle disease.
Select...
I have had cancer before, but it wasn't ovarian cancer or a non-melanoma skin cancer.
Select...
I have an active HIV infection.
Select...
I have active liver disease or cirrhosis.
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ from baseline until 12 months
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~from baseline until 12 months
Treatment Details
Study Objectives
Study objectives can provide a clearer picture of what you can expect from a treatment.Primary study objectives
Completion of the simvastatin intervention with at least 85% compliance
Secondary study objectives
Progression-free survival
Response by CA125
Awards & Highlights
No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.
Trial Design
1Treatment groups
Experimental Treatment
Group I: SimvastatinExperimental Treatment1 Intervention
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Simvastatin 40mg
2018
Completed Phase 2
~160
Find a Location
Who is running the clinical trial?
Bobbie Jo Rimel, MDLead Sponsor
Media Library
Eligibility Criteria:
This trial includes the following eligibility criteria:- You drink more than 5 alcoholic drinks every day.I do not have any unmanaged ongoing illnesses.I have taken statin medication before or am currently taking it.I am currently taking medications that interact with statins.I have been treated with doxorubicin or liposomal doxorubicin before.I have a long-term muscle disease.I have had cancer before, but it wasn't ovarian cancer or a non-melanoma skin cancer.I have an active HIV infection.Your hemoglobin A1C level is higher than 8.0%.I have active liver disease or cirrhosis.My ovarian cancer has returned but responds to platinum treatment.I am not allergic or unable to take carboplatin, liposomal doxorubicin, or simvastatin.
Research Study Groups:
This trial has the following groups:- Group 1: Simvastatin
Awards:
This trial has 1 awards, including:- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
Timeline:
This trial has the following timeline:- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Share this study with friends
Copy Link
Messenger